0001656472-24-000023.txt : 20240305
0001656472-24-000023.hdr.sgml : 20240305
20240305171335
ACCESSION NUMBER: 0001656472-24-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shlimak Anna
CENTRAL INDEX KEY: 0001804953
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38403
FILM NUMBER: 24722223
MAIL ADDRESS:
STREET 1: 720 KING STREET WEST, SUITE 320
CITY: TORONTO
STATE: A6
ZIP: M5V 2T3
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cronos Group Inc.
CENTRAL INDEX KEY: 0001656472
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 PETER STREET
STREET 2: SUITE 300
CITY: TORONTO
STATE: A6
ZIP: M5V 2H1
BUSINESS PHONE: (416) 504-0004
MAIL ADDRESS:
STREET 1: 111 PETER STREET
STREET 2: SUITE 300
CITY: TORONTO
STATE: A6
ZIP: M5V 2H1
FORMER COMPANY:
FORMER CONFORMED NAME: PharmaCan Capital Corp.
DATE OF NAME CHANGE: 20151021
4
1
wk-form4_1709676787.xml
FORM 4
X0508
4
2024-03-01
0
0001656472
Cronos Group Inc.
CRON
0001804953
Shlimak Anna
111 PETER STREET, SUITE 300
TORONTO
A6
M5V 2H1
ONTARIO, CANADA
0
1
0
0
See Remarks
0
COMMON SHARES
2024-03-01
4
M
0
7337
0
A
120020
D
COMMON SHARES
2024-03-01
4
F
0
2175
2.08
D
117845
D
RESTRICTED STOCK UNITS
2024-03-01
4
M
0
7337
0
D
COMMON SHARES
7337
195678
D
Each restricted stock unit ("RSU") represents a contingent right to receive one common share of Cronos Group Inc.
Due to an inadvertent error, the Form 4 filed by the Reporting Person on May 15, 2023 incorrectly reported the amount of securities beneficially owned following reported transaction(s). This inadvertent error caused the amount of securities beneficially owned to be overstated by 21,403 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following reported transaction(s).
On March 1, 2021, the Reporting Person was granted 22,009 RSUs, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
Due to an inadvertent error, the Form 4 filed by the Reporting Person on May 15, 2023 incorrectly reported the number of derivative securities beneficially owned following reported transaction(s). This inadvertent error caused the number of derivative securities beneficially owned to be understated by 153,772 shares. The new amount reported in Column 9 reports the correct number of derivative securities beneficially owned following reported transaction(s).
Senior Vice President, Corporate Affairs and Strategy
/s/ Aaron Werner, as attorney-in-fact for Anna Shlimak
2024-03-05